Search

The authors report a novel, effective and enhanced method of conjugating anticancer drug, paclitaxel and gallic acid with magnetosomes. Here, anticancer drugs were functionalised with magnetosomes membrane by direct and indirect (via crosslinkers: glutaraldehyde and 3‐aminopropyltriethoxysilane) adsorption methods. The prepared magnetosome–drug conjugates were characterised by Fourier transform infrared, zeta potential, field‐emission scanning electron microscope and thermogravimetric analysis/differential scanning calorimetry. The drug‐loading efficiency and capacity were found to be 87.874% for paclitaxel (MP) and 71.3% for gallic acid (MG), respectively as calculated by ultraviolet spectroscopy and high‐performance liquid chromatography. The drug release demonstrated by the diffusion method in phosphate buffer (PBS), showing a prolonged drug release for MP and MG, respectively. The cytotoxicity effect of the MP and MG displayed cytotoxicity of 69.71%, 55.194% against HeLa and MCF‐7 cell lines, respectively. The reactive oxygen species, acridine orange and ethidium bromide and 4, 6‐diamidino‐2‐phenylindole staining of the drug conjugates revealed the apoptotic effect of MP and MG. Further, the regulation of tumour suppressor protein, p53 was determined by western blotting which showed an upregulation of p53. Comparatively, the magnetosome–drug conjugates prepared by direct adsorption achieved the best effects on the drug‐loading efficiency and the increased percentage of cancer cell mortality and the upregulation of P53. The proposed research ascertains that magnetosomes could be used as effective nanocarriers in cancer therapy. [ABSTRACT FROM AUTHOR]

Cancer is a major cause of death. Thus, the incidence and mortality rate of cancer is globally important. Regarding vast problems caused by chemotherapy drugs, efforts have progressed to find new anti‐cancer drugs. Pyrazole derivatives are known as components with anti‐cancer properties. In here, Fe3 O4 nanoparticles were first functionalized with (3‐chloropropyl) trimethoxysilane, then 2‐((pyrazol‐4‐yl) methylene) hydrazinecarbothioamide (P) was anchored on the surface of magnetic nanoparticles (PL). The synthesized nano‐compounds were characterized using Fourier transform infrared spectroscopy, X‐ray diffraction, scanning electron microscopy, Zeta potential, dynamic light scattering, and energy‐dispersive x‐ray spectrometry analyses. The cytotoxicity effect was evaluated using MTT assay, apoptosis test by Flow cytometry, cell cycle analysis, Caspase‐3 activity assay and Hoechst staining on MCF‐7 cell line. The high toxicity for tumor cells and low toxicity on normal cells (MCF10A) was considered as an important feature (selectivity index, 10.9). Based on results, the IC50 for P and PL compounds were 157.80 and 131.84 μM/ml respectively. Moreover, apoptosis inducing, nuclear fragmentation, Caspase 3 activity and induction of cell rest in sub‐G1 and S phases, were also observed. The inhibitory effect of PL was significantly higher than P, which could be due to the high penetrability of Fe3 O4 nanoparticles. [ABSTRACT FROM AUTHOR]

Drug delivery is one of the most important challenges in the domain of health. Non‐toxic and biocompatible carriers are provided by human serum albumin nano‐capsule (HSA/NC) for drug delivery applications. In this study, HSA, with high loadings of drug‐modified cobalt ferrite (CoFe2 O4) magnetic nanoparticle (CoFe2 O4 /MNPs) was fabricated for epirubicin anticancer drug delivery. In the initial step, CoFe2 O4 /MNPs was synthesised via co‐precipitation technique and characterised by X‐ray powder diffraction, vibrating sample magnetometry, energy dispersive X‐ray analysis, scanning electron microscopy and map analysis. Furthermore, CoFe2 O4 /MNPs and epirubicin were loaded into HSA/NC and utilised as a novel system against breast cancer cell line (MCF‐7). IC50 for free epirubicin, unloaded CoFe2 O4 /MNPs/HSA/NC, CoFe2 O4 /MNPs and epirubicin‐loaded CoFe2 O4 /MNPs/HSA/NC were 7.7, 2400, 840 and 430 μg/ml, respectively. The results obtained revealed high cytotoxicity effect of epirubicin‐loaded CoFe2 O4 /MNPs on breast cancer cell line. [ABSTRACT FROM AUTHOR]

In this study, carvacrol‐loaded human serum albumin (HSA) nanoparticles were developed and characterised. Nanoparticles were prepared by desolvation and emulsion/desolvation methods. Encapsulation efficiency (EE%) and loading capacity (LC%) of nanoparticles prepared by desolvation method were 48.4 and 45.1%, respectively. Carvacrol‐loaded nanoparticles had 132 ± 42 nm in diameter with monomodal distribution. Carvacrol‐loaded nanoparticles which is prepared by emulsion/desolvation method had EE% and LC% of 32 and 32.3%, respectively, and 230 ± 38 nm in size. The release of carvacrol from nanoparticles was monitored in phosphate‐buffered saline (pH = 7.4), 100 rpm at 37°C for 10 days. About 21.4% of carvacrol was released after 3 h from nanoparticles that were prepared by desolvation method. In emulsion/desolvation method, 26.8% of total carvacrol was released during 3 h of incubation. Cytotoxicity effect of loaded carvacrol was assessed by 3‐[4, 5 dimethylthiazol‐2‐yl]‐2,5‐diphenyltetrazolium bromide (MTT) test on gastric cancer cells line (AGS). Cell line was exposed to the free carvacrol, unloaded and carvacrol‐loaded nanoparticles for 48 h. The half maximal inhibitory concentration (IC50) for free carvacrol, unloaded and carvacrol‐loaded HSA nanoparticles were 30, 1070 and 120 µg/ml, respectively. In conclusion, the results of this study showed applications of HSA nanoparticles for entrapment of carvacrol and antigastric cancer activity. Moreover, loading of carvacrol in combination with chemotherapy agents into the HSA nanoparticles may treat cancer cells better than single drug loaded nanoparticles. [ABSTRACT FROM AUTHOR]